Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with 18F-FAHA

Epigenetic modifications mediated by histone deacetylases (HDACs) play important roles in the mechanisms of different neurologic diseases and HDAC inhibitors (HDACIs) have shown promise in therapy. However, pharmacodynamic profiles of many HDACIs in the brain remain largely unknown due to the lack of validated methods for noninvasive imaging of HDAC expression-activity. In this study, dynamic PET/CT imaging was performed in 4 rhesus macaques using [(18)F]FAHA, a novel HDAC substrate, and [(18)F]fluoroacetate, the major radio-metabolite of [(18)F]FAHA, and fused with corresponding MR images of the brain. Quantification of [(18)F]FAHA accumulation in the brain was performed using a customized dual-tracer pharmacokinetic model. Immunohistochemical analyses of brain tissue revealed the heterogeneity of expression of individual HDACs in different brain structures and cell types and confirmed that PET/CT/MRI with [(18)F]FAHA reflects the level of expression-activity of HDAC class IIa enzymes. Furthermore, PET/CT/MRI with [(18)F]FAHA enabled non-invasive, quantitative assessment of pharmacodynamics of HDAC inhibitor SAHA in the brain.

[1]  T. Abel,et al.  Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. , 2008, Current opinion in pharmacology.

[2]  N. Volkow,et al.  Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography , 2010 .

[3]  S. Petri,et al.  Differential Histone Deacetylase mRNA Expression Patterns in Amyotrophic Lateral Sclerosis , 2010, Journal of neuropathology and experimental neurology.

[4]  E. Thomas.  Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors , 2009, Molecular Neurobiology.

[5]  U. Koch,et al.  Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases , 2007, Proceedings of the National Academy of Sciences.

[6]  M. K. Meintzer,et al.  Inactivation of the Myocyte Enhancer Factor-2 Repressor Histone Deacetylase-5 by Endogenous Ca2//Calmodulin-dependent Kinase II Promotes Depolarization-mediated Cerebellar Granule Neuron Survival* , 2003, Journal of Biological Chemistry.

[7]  W. Bornmann,et al.  Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy , 2006, Molecular Cancer Therapeutics.

[8]  Eric J. Nestler,et al.  Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.

[9]  L. Heidmets,et al.  Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice , 2007, Behavioural Brain Research.

[10]  L. Crepaldi,et al.  Chromatin learns to behave , 2009, Epigenetics.

[11]  J. Cha,et al.  Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). , 2006, Current Alzheimer research.

[12]  D. Clarke.  Fluoroacetate and fluorocitrate: Mechanism of action , 1991, Neurochemical Research.

[13]  Dimitris Thanos,et al.  Integration of Long-Term-Memory-Related Synaptic Plasticity Involves Bidirectional Regulation of Gene Expression and Chromatin Structure , 2002, Cell.

[14]  R. Ferrante,et al.  Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice , 2005, Journal of neurochemistry.

[15]  A. Contestabile,et al.  Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. , 2009, Current molecular pharmacology.

[16]  E. Nestler,et al.  Epigenetics in the Nervous System , 2008, The Journal of Neuroscience.

[17]  A. Chiarugi,et al.  Pharmacological Inhibition of Histone Deacetylases by Suberoylanilide Hydroxamic Acid Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain , 2006, Molecular Pharmacology.

[18]  A. Barco,et al.  Selective Boosting of Transcriptional and Behavioral Responses to Drugs of Abuse by Histone Deacetylase Inhibition , 2009, Neuropsychopharmacology.

[19]  N. Volkow,et al.  Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. , 2010, ACS chemical neuroscience.

[20]  G. Bates,et al.  Histone deacetylase inhibitors as therapeutics for polyglutamine disorders , 2006, Nature Reviews Neuroscience.

[21]  R. De Francesco,et al.  Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. , 2008, Bioorganic & medicinal chemistry letters.

[22]  H. L. Carrell,et al.  Fluorocitrate Inhibition of Aconitase: Relative Configuration of Inhibitory Isomer by X-ray Crystallography , 1970, Science.

[23]  L. Tsai,et al.  Targeting the correct HDAC(s) to treat cognitive disorders. , 2010, Trends in pharmacological sciences.

[24]  E. Nestler,et al.  Histone acetylation in drug addiction. , 2009, Seminars in cell & developmental biology.

[25]  Jason S. Lewis,et al.  The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. , 2011, Nuclear medicine and biology.

[26]  L. Thompson,et al.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders , 2008, Nature Reviews Drug Discovery.

[27]  C. Stout,et al.  The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Scott J. Russo,et al.  Chromatin Remodeling Is a Key Mechanism Underlying Cocaine-Induced Plasticity in Striatum , 2005, Neuron.

[29]  T. Yao,et al.  Intracellular Trafficking of Histone Deacetylase 4 Regulates Neuronal Cell Death , 2005, The Journal of Neuroscience.

[30]  A. Mai,et al.  Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. , 2009, Current pharmaceutical design.

[31]  O. Mawlawi,et al.  Whole-Body Biodistribution Kinetics, Metabolism, and Radiation Dosimetry Estimates of 18F-PEG6-IPQA in Nonhuman Primates , 2011, The Journal of Nuclear Medicine.

[32]  Luc Pellerin,et al.  Monocarboxylate transporters in the central nervous system: distribution, regulation and function , 2005, Journal of neurochemistry.

[33]  S. Minucci,et al.  New method to detect histone acetylation levels by flow cytometry , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[34]  P. Casaccia,et al.  HDAC inhibitors and neurodegeneration: at the edge between protection and damage. , 2010, Pharmacological research.

[35]  J. A. Hendricks,et al.  In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). , 2011, Journal of medicinal chemistry.

[36]  J. Gelovani,et al.  Radiosynthesis of 6-([18F]fluoroacetamido)-1-hexanoic-anilide ([18F]FAHA) for PET imaging of histone deacetylase (HDAC) , 2006 .

[37]  Guanghua Xiao,et al.  Histone Deacetylase 5 Epigenetically Controls Behavioral Adaptations to Chronic Emotional Stimuli , 2007, Neuron.

[38]  Xin-Min Li,et al.  Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats , 2003, Brain Research.

[39]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[40]  L. Bidaut,et al.  Pharmacokinetics, Metabolism, Biodistribution, Radiation Dosimetry, and Toxicology of 18F-Fluoroacetate (18F-FACE) in Non-human Primates , 2012, Molecular Imaging and Biology.

[41]  H. Bading,et al.  Neuronal activity‐dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5 , 2003, Journal of neurochemistry.

[42]  C. Pérez-Plasencia,et al.  Molecular Cancer Histone Acetylation and Histone Deacetylase Activity of Magnesium Valproate in Tumor and Peripheral Blood of Patients with Cervical Cancer. a Phase I Study , 2005 .

[43]  B. Morrison,et al.  Class IIA HDACs in the regulation of neurodegeneration. , 2008, Frontiers in bioscience : a journal and virtual library.

[44]  E. Nestler,et al.  Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.

[45]  F. Bloom,et al.  Distribution of histone deacetylases 1–11 in the rat brain , 2007, Journal of Molecular Neuroscience.

[46]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Ugale,et al.  Brain Chromatin Remodeling: A Novel Mechanism of Alcoholism , 2008, The Journal of Neuroscience.

[48]  F. Fonnum,et al.  Use of fluorocitrate and fluoroacetate in the study of brain metabolism , 1997, Glia.

[49]  J. Keil,et al.  Sodium fluoroacetate poisoning. , 1975, American journal of diseases of children.

[50]  Richard O Jenkins,et al.  Toxicology of fluoroacetate: a review, with possible directions for therapy research , 2006, Journal of applied toxicology : JAT.

[51]  N. Volkow,et al.  Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. , 2009, Nuclear medicine and biology.

[52]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[53]  R. Peters,et al.  Biochemistry of fluoroacetate poisoning. The isolation and some properties of the fluorotricarboxylic acid inhibitor of citrate metabolism , 1953, Proceedings of the Royal Society of London. Series B - Biological Sciences.